Skip to search formSkip to main contentSkip to account menu

TAK 285

Known as: EGFR/HER2 Kinase Inhibitor TAK-285, TAK-285, TAK285 
An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The human epidermal growth factor receptor (HER) family plays a major role in cancer cell proliferation. Overexpression of these… 
Highly Cited
2013
Highly Cited
2013
The epidermal growth factor receptor (EGFR) family plays a critical role in vital cellular processes and in various cancers… 
2013
2013
Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors… 
2013
2013
SummaryIntroduction This phase 1 study assessed safety, maximum tolerated dose (MTD), pharmacokinetics, cerebrospinal fluid (CSF… 
2012
2012
Background:This phase I first-in-human study was conducted in Japanese patients to investigate the safety, pharmacokinetics (PKs… 
Highly Cited
2011
Highly Cited
2011
Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been… 
Highly Cited
2011
Highly Cited
2011
Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is…